Citations (61)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (24)
Niki Katsiki, Genovefa Kolovou, Pablo Perez-Martinez & Dimitri P. Mikhailidis. (2018) Dyslipidaemia in the elderly: to treat or not to treat?. Expert Review of Clinical Pharmacology 11:3, pages 259-278.
Read now
Read now
Marilisa Bove, Federica Fogacci & Arrigo F. G. Cicero. (2017) Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia. Expert Opinion on Drug Metabolism & Toxicology 13:10, pages 1099-1104.
Read now
Read now
Engi Abdel-Hady Algharably, Iris Filler, Stephanie Rosenfeld, Katja Grabowski & Reinhold Kreutz. (2017) Statin intolerance – a question of definition. Expert Opinion on Drug Safety 16:1, pages 55-63.
Read now
Read now
Yi-Chung Shih & Huan-Sheng Lin. (2017) Effectiveness of fixed-dose ezetimibe+simvastatin in real-life hypercholesterolaemia treatment: a retrospective observational study in Taiwan. Clinical Lipidology 12:1, pages 45-55.
Read now
Read now
Jaideep Patel, Seth S Martin & Maciej Banach. (2016) Expert opinion: the therapeutic challenges faced by statin intolerance. Expert Opinion on Pharmacotherapy 17:11, pages 1497-1507.
Read now
Read now
Aris P Agouridis, Devaki R Nair & Dimitri P Mikhailidis. (2015) Strategies to overcome statin intolerance. Expert Opinion on Drug Metabolism & Toxicology 11:6, pages 851-855.
Read now
Read now
JoAnne M Foody, Peter P Toth, Andrew M Tershakovec, Thomas Musliner, Joanne E Tomassini, Robert S Lowe, David R Neff & Harry R Davis. (2014) Efficacy and safety of ezetimibe plus atorvastatin therapy. Clinical Lipidology 9:4, pages 441-470.
Read now
Read now
Victoria Zysek, Jocelyn Spoon & Stephen Kopecky. (2013) Mayo Clinic: management of patients with statin intolerance. Clinical Lipidology 8:5, pages 541-549.
Read now
Read now
Niki Katsiki, Vasilios G. Athyros & Asterios Karagiannis. (2013) Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?. Journal of Drug Assessment 2:1, pages 67-71.
Read now
Read now
Binh An P Phan, Thomas D Dayspring & Peter P Toth. (2012) Ezetimibe therapy: mechanism of action and clinical update. Vascular Health and Risk Management 8, pages 415-427.
Read now
Read now
Marcello Arca & Giovanni Pigna. (2011) Treating statin-intolerant patients. Diabetes, Metabolic Syndrome and Obesity 4, pages 155-166.
Read now
Read now
Matilda Florentin, Evangelos N Liberopoulos, Dimitri P Mikhailidis & Moses S Elisaf. (2011) Emerging options in the treatment of dyslipidemias: a bright future?. Expert Opinion on Emerging Drugs 16:2, pages 247-270.
Read now
Read now
Thura T Abd & Terry A Jacobson. (2011) Statin-induced myopathy: a review and update. Expert Opinion on Drug Safety 10:3, pages 373-387.
Read now
Read now
DJ Blom. (2011) Statins: adherence and side-effects. South African Family Practice 53:3, pages 205-215.
Read now
Read now
Niki Katsiki, Vasilis G. Athyros, Asterios Karagiannis & Dimitri P. Mikhailidis. (2011) Ezetimibe and low density lipoprotein subfractions: an ongoing debate. Current Medical Research and Opinion 27:3, pages 693-695.
Read now
Read now
Matilda Florentin, Evangelos N. Liberopoulos, Elisavet Moutzouri, Christos V. Rizos, Alexandros D. Tselepis & Moses S. Elisaf. (2011) The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Current Medical Research and Opinion 27:3, pages 685-692.
Read now
Read now
Maria Sarigianni, Niki Katsiki & Dimitri P Mikhailidis. (2010) Ezetimibe in diabetes: more than cholesterol lowering?. Current Medical Research and Opinion 26:10, pages 2517-2520.
Read now
Read now
I. Migdalis, A. Efthimiadis, St. Pappas, D. Alexopoulos, F. Vlasserou & D. P. Mikhailidis. (2009) Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Current Medical Research and Opinion 25:10, pages 2571-2576.
Read now
Read now
V. G. Athyros, A. Karagiannis, A. I. Hatzitolios, K. Paletas, C. Savopoulos, G. Giannoglou & D. P. Mikhailidis. (2009) Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. Current Medical Research and Opinion 25:4, pages 971-980.
Read now
Read now
ES Nakou, TD Filippatos, DN Kiortsis, CS Derdemezis, AD Tselepis, DP Mikhailidis & MS Elisaf. (2008) The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opinion on Pharmacotherapy 9:18, pages 3151-3158.
Read now
Read now
Zlatko Fras & Dimitri P Mikhailidis. (2008) Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. Current Medical Research and Opinion 24:9, pages 2467-2476.
Read now
Read now
CS Derdemezis, TD Filippatos, AD Tselepis, DP Mikhailidis & MS Elisaf. (2008) Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Expert Opinion on Pharmacotherapy 9:11, pages 1829-1837.
Read now
Read now
E. S. Nakou, T. D. Filippatos, M. Georgoula, D. N. Kiortsis, A. D. Tselepis, D. P. Mikhailidis & M. S. Elisaf. (2008) The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Current Medical Research and Opinion 24:7, pages 1919-1929.
Read now
Read now
M. Florentin, E. N. Liberopoulos, D. P. Mikhailidis & M. S. Elisaf. (2008) Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Current Medical Research and Opinion 24:4, pages 995-1009.
Read now
Read now
Articles from other publishers (37)
Zlatko Fras & Dimitri P. Mikhailidis. (2021) Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease). Current Vascular Pharmacology 19:5, pages 451-468.
Crossref
Crossref
Niki Katsiki & Dimitri P Mikhailidis. (2018) Lipids: a personal view of the past decade. Hormones 17:4, pages 461-478.
Crossref
Crossref
Elizabeth M. Masko, Mahmoud A. Alfaqih, Keith R. Solomon, William T. Barry, Christopher B. Newgard, Michael J. Muehlbauer, Nikolaos A. Valilis, Tameika E. Phillips, Susan H. Poulton, Alexis R. Freedland, Stephanie Sun, Shweta K. Dambal, Sergio E. Sanders, Everardo Macias, Michael R. Freeman, Mark W. Dewhirst, Salvatore V. Pizzo & Stephen J. Freedland. (2017) Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model. The Prostate 77:5, pages 446-457.
Crossref
Crossref
Vasilios G. Athyros, Niki Katsiki & Dimitri P. Mikhailidis. (2016) Statins, renal function and homocysteine. Pharmacological Reports 68:5, pages 1093.
Crossref
Crossref
Tisha R. Joy & Emily T. Brennan. (2016) Management strategies in patients with statin-associated muscle symptoms: What is the best strategy?. Journal of Clinical Lipidology 10:5, pages 1067-1072.
Crossref
Crossref
Niki Katsiki, Vasilios G. Athyros & Dimitris P. Mikhailidis. (2016) More news from IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial). Hormones 15:1, pages 5-7.
Crossref
Crossref
Helle Wallach-Kildemoes & Ebba Holme Hansen. (2015) Sociodemographic and diagnostic characteristics of prescribing a second-line lipid-lowering medication: ezetimibe used as initial medication, switch from statins, or add-on medication. European Journal of Clinical Pharmacology 71:10, pages 1245-1254.
Crossref
Crossref
George N. Kouvelos, Eleni M. Arnaoutoglou, Haralampos J. Milionis, Vaia D. Raikou, Nektario Papa & Miltiadis I. Matsagkas. (2014) The Effect of Adding Ezetimibe to Rosuvastatin on Renal Function in Patients Undergoing Elective Vascular Surgery. Angiology 66:2, pages 128-135.
Crossref
Crossref
Alberico L. Catapano, Michel Farnier, JoAnne M. Foody, Peter P. Toth, Joanne E. Tomassini, Philippe Brudi & Andrew M. Tershakovec. (2014) Combination therapy in dyslipidemia: Where are we now?. Atherosclerosis 237:1, pages 319-335.
Crossref
Crossref
Jennifer A. Shannon, Samuel M. John, Harish S. Parihar, Shari N. Allen & Jenna J. Ferrara. (2013) A Clinical Review of Statin-Associated Myopathy. Journal of Pharmacy Technology 29:5, pages 219-230.
Crossref
Crossref
Kosmas I. Paraskevas, Andrew N. Nicolaides & Dimitri P. Mikhailidis. (2013) Statins and Venous Thromboembolism. Angiology 64:7, pages 489-491.
Crossref
Crossref
Elisavet Moutzouri, Evangelos N. Liberopoulos, Matilda Florentin, George Liamis & Moses S. Elisaf. (2012) Effects of Statin Monotherapy Versus Statin Plus Ezetimibe Combination on Serum Uric Acid Levels. Journal of Cardiovascular Pharmacology and Therapeutics 18:1, pages 13-18.
Crossref
Crossref
Sang-Hak Lee & Donghoon Choi. (2012) Response to Letter on “Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipedemia”. Journal of Cardiovascular Pharmacology and Therapeutics 17:4, pages 428-428.
Crossref
Crossref
Michael S. Kostapanos, Moses S. Elisaf & Dimitri P. Mikhailidis. (2012) Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipidemia. Journal of Cardiovascular Pharmacology and Therapeutics 17:4, pages 427-427.
Crossref
Crossref
Takashi Maekawa, Kimihiro Komori, Kouichi Morisaki & Takeo Itoh. (2012) Ezetimibe reduces intimal hyperplasia in rabbit jugular vein graft. Journal of Vascular Surgery 56:6, pages 1689-1697.
Crossref
Crossref
Michael J Koren, Rob Scott, Jae B Kim, Beat Knusel, Thomas Liu, Lei Lei, Michael Bolognese & Scott M Wasserman. (2012) Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. The Lancet 380:9858, pages 1995-2006.
Crossref
Crossref
Michael S Kostapanos, Dimitri P Mikhailidis & Moses S Elisaf. (2012) Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?. Future Cardiology 8:6, pages 813-817.
Crossref
Crossref
Loukianos S. Rallidis, Katerina Fountoulaki & Maria Anastasiou-Nana. (2012) Managing the underestimated risk of statin-associated myopathy. International Journal of Cardiology 159:3, pages 169-176.
Crossref
Crossref
Thomas F. WhayneJrJr. (2011) Statin Myopathy: Significant Problem With Minimal Awareness by Clinicians and no Emphasis by Clinical Investigators. Angiology 62:5, pages 415-421.
Crossref
Crossref
Ram Y. Gordon & David J. Becker. (2010) The Role of Red Yeast Rice for the Physician. Current Atherosclerosis Reports 13:1, pages 73-80.
Crossref
Crossref
Piero RuggenentiAnnalisa PernaGiuseppe Remuzzi. (2010) Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A Prospective Randomized Double-Blind Clinical Trial. Diabetes Care 33:10, pages e133-e133.
Crossref
Crossref
Maria SarigianniNiki KatsikiDimitri P. Mikhailidis. (2010) Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A Prospective Randomized Double-Blind Clinical Trial. Diabetes Care 33:10, pages e132-e132.
Crossref
Crossref
Charles R. Harper & Terry A. Jacobson. (2010) Evidence-Based Management of Statin Myopathy. Current Atherosclerosis Reports 12:5, pages 322-330.
Crossref
Crossref
K. Berneis, M. Rizzo, H. K. Berthold, G. A. Spinas, W. Krone & I. Gouni-Berthold. (2010) Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. European Heart Journal 31:13, pages 1633-1639.
Crossref
Crossref
Christos S. Derdemezis, Theodosios D. Filippatos, Dimitri P. Mikhailidis & Moses S. Elisaf. (2010) Review Article: Effects of Plant Sterols and Stanols Beyond Low-Density Lipoprotein Cholesterol Lowering. Journal of Cardiovascular Pharmacology and Therapeutics 15:2, pages 120-134.
Crossref
Crossref
Todd C. Rideout, Scott V. Harding, Christopher P.F. Marinangeli & Peter J.H. Jones. (2010) Combination drug–diet therapies for dyslipidemia. Translational Research 155:5, pages 220-227.
Crossref
Crossref
Michalis Kalogirou, Vasilis Tsimihodimos & Moses Elisaf. (2010) Pleiotropic effects of ezetimibe: Do they really exist?. European Journal of Pharmacology 633:1-3, pages 62-70.
Crossref
Crossref
Yiannis S. Chatzizisis, Konstantinos C. Koskinas, Gesthimani Misirli, Christos Vaklavas, Apostolos Hatzitolios & George D. Giannoglou. (2010) Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy. Drug Safety 33:3, pages 171-187.
Crossref
Crossref
Matilda Florentin, Michael S. Kostapanos, Eleni S. Nakou, Moses ElisafEvangelos N. Liberopoulos. (2009) Efficacy and Safety of Ezetimibe Plus Orlistat or Rimonabant in Statin-Intolerant Nondiabetic Overweight/Obese Patients With Dyslipidemia. Journal of Cardiovascular Pharmacology and Therapeutics 14:4, pages 274-282.
Crossref
Crossref
Konstantinos Tziomalos, Emmanuel S Ganotakis, Irene F Gazi, Devaki R Nair & Dimitri P Mikhailidis. (2009) Kidney Function and Estimated Vascular Risk in Patients with Primary Dyslipidemia. The Open Cardiovascular Medicine Journal 3:1, pages 57-68.
Crossref
Crossref
. (2009) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 16:2, pages 189-202.
Crossref
Crossref
György Paragh, Gyula Pados, László Márk, István Karádi, Mária Audikovszky, Károly Zámolyi & László Romics. (2008) To What Extent are National Cardiovascular Disease Preventive Guidelines Accomplished in Hungary? The Goal Attainment Program (GAP). Hungarian Medical Journal 2:4, pages 593-602.
Crossref
Crossref
Hanna Slim & Paul D. Thompson. (2008) Ezetimibe-related myopathy: A systematic review. Journal of Clinical Lipidology 2:5, pages 328-334.
Crossref
Crossref
Terry A. Jacobson. (2008) Toward “Pain-Free” Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia. Mayo Clinic Proceedings 83:6, pages 687-700.
Crossref
Crossref
Terry A. Jacobson. (2008) Toward “Pain-Free” Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia. Mayo Clinic Proceedings 83:6, pages 687-700.
Crossref
Crossref
Adam P. Levine, Dimitri P. MikhailidisTessa Moross, Karen Benson & Mayur Gor. (2008) Achieving Vascular Risk Factor Targets: A Survey of a London General Practice. Angiology 59:1, pages 36-46.
Crossref
Crossref
Vasilios G. Athyros, Konstantinos Tziomalos, Anna I. Kakafika, Haralambos Koumaras, Asterios Karagiannis & Dimitri P. Mikhailidis. (2008) Effectiveness of Ezetimibe Alone or in Combination With Twice a Week Atorvastatin (10 mg) for Statin Intolerant High-Risk Patients. The American Journal of Cardiology 101:4, pages 483-485.
Crossref
Crossref